drugset / Trial / NCT00979602

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

NCT00979602

Phase 3 Completed 4048 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to characterize the safety, immunogenicity, and relative efficacy of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of age or older.

Timeline

Start
2009-11-09
Primary completion
2011-01-10
Completion
2011-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK2340273A Vaccine 15 ug Intramuscular
Subject GSK2340274A Vaccine 3.75 ug Intramuscular

Indications